Evidence map›Paper›PMID 40084358›Full record

ArticleAmerican journal of cancer research2025

Early-phase clinical trials in the pandemic era: a four-year experience from an academic cancer center.

Katie Moreland, Bethany Fuhrman, Kayla Webb, Melanie Margraf, Jessica Wernke, Christine Vollmer, Alison Kastl, Michelle Marcum, Jennifer Leddon, Amanda Jackson and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Katie MorelandDepartment of Internal Medicine, College of Medicine, University of Cincinnati Cincinnati, Ohio 45229, USA.
Bethany FuhrmanUniversity of Cincinnati Cancer Center, College of Medicine, University of Cincinnati Cincinnati, Ohio 45267, USA.
Kayla WebbUniversity of Cincinnati Cancer Center, College of Medicine, University of Cincinnati Cincinnati, Ohio 45267, USA.
Melanie MargrafUniversity of Cincinnati Cancer Center, College of Medicine, University of Cincinnati Cincinnati, Ohio 45267, USA.
Jessica WernkeUniversity of Cincinnati Cancer Center, College of Medicine, University of Cincinnati Cincinnati, Ohio 45267, USA.
Christine VollmerUniversity of Cincinnati Cancer Center, College of Medicine, University of Cincinnati Cincinnati, Ohio 45267, USA.
Alison KastlUniversity of Cincinnati Cancer Center, College of Medicine, University of Cincinnati Cincinnati, Ohio 45267, USA.
Michelle MarcumUniversity of Cincinnati Cancer Center, College of Medicine, University of Cincinnati Cincinnati, Ohio 45267, USA.
Jennifer LeddonDepartment of Internal Medicine, College of Medicine, University of Cincinnati Cincinnati, Ohio 45229, USA.
Amanda JacksonDepartment of Internal Medicine, College of Medicine, University of Cincinnati Cincinnati, Ohio 45229, USA.
Emily CurranDepartment of Internal Medicine, College of Medicine, University of Cincinnati Cincinnati, Ohio 45229, USA.
Shesh RaiUniversity of Cincinnati Cancer Center, College of Medicine, University of Cincinnati Cincinnati, Ohio 45267, USA.
Trisha Wise-DraperDepartment of Internal Medicine, College of Medicine, University of Cincinnati Cincinnati, Ohio 45229, USA.
Davendra SohalDepartment of Internal Medicine, College of Medicine, University of Cincinnati Cincinnati, Ohio 45229, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Early-phase clinical trials are the first step in cancer drug development. However, they are becoming difficult to conduct - increased complexity of treatments, multiple stakeholders, and most importantly, the changes imposed by the COVID19 pandemic. We report our experience during and since the pandemic, focusing on early-phase clinical trials for solid tumors. From 2020-2023, our accruals improved by 161% (from 33 to 86). We consented 260 patients; of those, 176 (68%) fulfilled all eligibility criteria and started therapy - trials included immunotherapy (74, 42%), targeted therapy (43, 24%), novel molecules (30, 17%), cellular therapy/oncolytic viruses (19, 11%), and pharmacokinetic assessment trials of standard therapies (10, 6%). We increased staffing from 4 to 12 over this period, instituted hybrid work policies, created a dedicated triage nurse to reduce screen failures, and developed disease-specific sub-teams for better efficiencies and lower error rates. These efforts allowed us to improve the quantity and quality of our accruals.

Indexed as

academic cancer centerClinical trialoncologyphase 1

Identifiers

PMID40084358
PMCPMC11897621

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.